Clinical Trial Update: Long-term Study of TAK-875 [Phase 3]

View source ↗

Summary

TAK-875 (fasiglifam) from Takeda completed its long-term Phase 3 trial in diabetes mellitus. The update indicates the study status is COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• TAK-875 (fasiglifam)

Snippet

Sponsor: Takeda | Conditions: Diabetes Mellitus | Phase 3 | Status: COMPLETED